Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
Dario Tuccinardi, Assistant Professor in Endocrinology at The Bio-Medical University of Rome, shared on LinkedIn:
”Obesity is no longer just a cardiovascular risk factor. It is a cardiovascular treatment target.
Obesity and visceral adiposity actively shape cardiovascular disease, through inflammation, altered myocardial energetics, and diagnostic distortion.
Yet in daily practice, patients with obesity are still affected by clinical bias: symptoms are under-recognized, biomarkers misinterpreted, and treatment decisions delayed or diluted.
Our review argues for a double shift.
First: therapeutic.
Modern anti-obesity pharmacotherapy, especially GLP-1 receptor agonists and dual-incretin agents, extends beyond weight loss.
These drugs improve endothelial function, reduce inflammation, optimize myocardial metabolism, and now demonstrate cardiovascular event reduction even in people with obesity without diabetes.
Second: cultural and clinical.
Cardiologists must be supported in overcoming weight-related bias—moving beyond BMI, recognizing visceral obesity, correctly interpreting biomarkers, and confidently treating obesity as part of cardiovascular care rather than deferring it.
Treating obesity is no longer optional.
It is evidence-based cardiovascular medicine.
Weight loss is not about weight.
It’s about outcomes.”

Stay updated on all scientific advances with Hemostasis Today.
-
Apr 25, 2026, 04:44Tareq Abadl: Not Every Rh-Positive or Rh-Negative Result is That Simple
-
Apr 25, 2026, 04:44Michael Makris: Data Security and Research Integrity in Population Biobanks
-
Apr 25, 2026, 04:43Muriel De Vos: Real-World Outcomes in Haemophilia A Without Inhibitors in the United States
-
Apr 25, 2026, 04:43Abdullah Alswied: The Role of Intra-Apheresis in Stem Cell Collection
-
Apr 25, 2026, 04:42Mohammed Elmourtada Abdulgayoom: Exploring Hyperbaric Oxygen Therapy in Sickle Cell Disease
-
Apr 25, 2026, 04:10Nour Al-Mozain: Highlights on Therapeutic Plateletpheresis in Thrombocytosis
-
Apr 25, 2026, 03:502026 Applications Open for The International Outreach Initiative – ASH
-
Apr 25, 2026, 02:51Roche Extends Support to Expand Global Access to Hemophilia Care – WFH
-
Apr 25, 2026, 02:44WFH Congress 2026 Participation Overview – WFH